MA51311A - Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents

Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Info

Publication number
MA51311A
MA51311A MA051311A MA51311A MA51311A MA 51311 A MA51311 A MA 51311A MA 051311 A MA051311 A MA 051311A MA 51311 A MA51311 A MA 51311A MA 51311 A MA51311 A MA 51311A
Authority
MA
Morocco
Prior art keywords
hbv
vaccines
hepatitis
virus
related uses
Prior art date
Application number
MA051311A
Other languages
English (en)
Inventor
Daniel Boden
Pooter Dorien De
Helen Horton
Jean-Marc Edmond Fernand Marie Neefs
Soumitra Roy
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA51311A publication Critical patent/MA51311A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA051311A 2017-12-19 2018-12-18 Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées MA51311A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607426P 2017-12-19 2017-12-19
IB2017058142 2017-12-19

Publications (1)

Publication Number Publication Date
MA51311A true MA51311A (fr) 2020-10-28

Family

ID=65199441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051311A MA51311A (fr) 2017-12-19 2018-12-18 Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Country Status (15)

Country Link
EP (2) EP3727445B1 (fr)
JP (1) JP7317017B2 (fr)
KR (1) KR20200101416A (fr)
CN (1) CN111836641A (fr)
AU (1) AU2018389787A1 (fr)
BR (1) BR112020011976A2 (fr)
CA (1) CA3086327A1 (fr)
ES (1) ES2963179T3 (fr)
IL (1) IL275427B2 (fr)
JO (1) JOP20200153A1 (fr)
MA (1) MA51311A (fr)
MX (3) MX2020006480A (fr)
PH (1) PH12020550924A1 (fr)
SG (1) SG11202005895QA (fr)
WO (1) WO2019123252A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ,インコーポレーテッド 遺伝子発現増強のための組成物および方法
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
EP3864027A1 (fr) 2018-10-08 2021-08-18 Janssen Pharmaceuticals, Inc. Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques
CA3141238A1 (fr) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Vaccins contre le virus de l'hepatite b (vhb) et utilisations associees
EP3986458A1 (fr) * 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
TW202245809A (zh) * 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
EP4370700A4 (fr) * 2021-07-16 2025-10-29 Univ Mcmaster Vaccin viral

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
ATE227118T1 (de) * 1993-08-02 2002-11-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
WO1998043702A2 (fr) 1997-04-03 1998-10-08 Iacob Mathiesen Methode pour introduire des medicaments et des acides nucleiques dans le muscle squelettique
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
EP2428250A1 (fr) 1998-07-13 2012-03-14 Genetronics, Inc. Thérapie génique ciblant la peau et les muscles par champ magnétique pulsé
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US6921534B2 (en) 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
KR101261642B1 (ko) 2004-03-08 2013-05-06 아이커 메디칼 시스템스 인코포레이티드 치료 제제의 전기 매개식 이송을 위한 개선된 장치
AU2007313203B2 (en) 2006-10-17 2012-08-16 Vgx Pharmaceuticals, Llc Electroporation devices and methods of using same for electroporation of cells in mammals
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Hbv 백신 및 그의 제조 방법
PE20140844A1 (es) * 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Hbv聚合酶突變體
NZ747635A (en) 2016-03-28 2024-05-31 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
WO2017176319A1 (fr) * 2016-04-06 2017-10-12 University Of Washington Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant l'antigène nucléocapsidique du vhb

Also Published As

Publication number Publication date
IL275427A (en) 2020-08-31
JP7317017B2 (ja) 2023-07-28
EP3727445B1 (fr) 2023-08-16
MX2020006480A (es) 2020-09-22
IL275427B1 (en) 2023-12-01
MX2020011802A (es) 2020-12-07
EP4272833A2 (fr) 2023-11-08
KR20200101416A (ko) 2020-08-27
CA3086327A1 (fr) 2019-06-27
AU2018389787A1 (en) 2020-06-25
CN111836641A (zh) 2020-10-27
WO2019123252A1 (fr) 2019-06-27
ES2963179T3 (es) 2024-03-25
EP3727445A1 (fr) 2020-10-28
MX2020011804A (es) 2020-12-07
EP4272833A3 (fr) 2024-01-10
BR112020011976A2 (pt) 2020-11-24
SG11202005895QA (en) 2020-07-29
EP3727445C0 (fr) 2023-08-16
PH12020550924A1 (en) 2021-05-31
IL275427B2 (en) 2024-04-01
JOP20200153A1 (ar) 2020-06-18
JP2021509107A (ja) 2021-03-18

Similar Documents

Publication Publication Date Title
IL275427A (en) Hepatitis virus vaccines HBV) B) and their uses
MA50813A (fr) Vaccins contre le virus d'epstein-barr
EP3325097A4 (fr) Compositions et agents contre le virus de l'hépatite b et utilisations de ceux-ci
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA49463A (fr) Vaccin contre le virus de l'herpès simplex
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
EP3439696A4 (fr) Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant l'antigène nucléocapsidique du vhb
MA55581A (fr) Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b
SG11201703638XA (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
EP3334833A4 (fr) Vaccins du virus de l'herpès de dinde recombinant et utilisations de celui-ci
MA56535A (fr) Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA56534A (fr) Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
IL255366A0 (en) Reagents for the treatment of hepatitis B infection and their use
IL273093A (en) Combination of drugs for the treatment of hepatitis B virus type HBV patients using Parafoxvirus Obis (PPVO) and at least one other antiviral agent
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
SG11201808266QA (en) Hepatitis b treatment vaccine on the basis of inactivated, fully recombinant hansenula cells expressing hbsag
IL277128A (en) Hepatitis B vaccines and their uses
MA45994A (fr) Vaccins contre des virus
IL290924A (en) Vaccines for hepatitis b virus
MA56524A (fr) Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
WO2014160088A3 (fr) Traitement d'infections par le virus de l'hépatite b
MA56533A (fr) Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1